Juergen K. Willmann, M.D.
Publication Details
-
Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55).
Radiology. 2010; (2): 519-27
To develop and test human kinase insert domain receptor (KDR)-targeted microbubbles (MBs) (MB(KDR)) for imaging KDR at the molecular level and for monitoring antiangiogenic therapy in a human colon cancer xenograft tumor model in mice.
Help